Disease-modifying drugs and Parkinson's disease.
Identifieur interne : 000C92 ( PubMed/Curation ); précédent : 000C91; suivant : 000C93Disease-modifying drugs and Parkinson's disease.
Auteurs : Hervé Allain [France] ; Danièle Bentué-Ferrer ; Yvette AkwaSource :
- Progress in neurobiology [ 0301-0082 ] ; 2008.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (pharmacology), Apoptosis (drug effects), Apoptosis (genetics), Brain (drug effects), Brain (metabolism), Brain (physiopathology), Cytoprotection (drug effects), Cytoprotection (physiology), Disease Models, Animal, Humans, Nerve Degeneration (drug therapy), Nerve Degeneration (genetics), Nerve Degeneration (physiopathology), Neuroprotective Agents (pharmacology), Parkinson Disease (drug therapy), Parkinson Disease (genetics), Parkinson Disease (physiopathology).
- MESH :
- chemical , pharmacology : Antiparkinson Agents, Neuroprotective Agents.
- drug effects : Apoptosis, Brain, Cytoprotection.
- drug therapy : Nerve Degeneration, Parkinson Disease.
- genetics : Apoptosis, Nerve Degeneration, Parkinson Disease.
- metabolism : Brain.
- physiology : Cytoprotection.
- physiopathology : Brain, Nerve Degeneration, Parkinson Disease.
- Animals, Disease Models, Animal, Humans.
Abstract
Symptomatic medications, l-Dopa and dopaminergic agents, remain the only clinically pertinent pharmacological treatment proven effective and available for the large population of patients with Parkinson's disease. The challenge for the pharmaceutical industry is to develop disease-modifying drugs which could arrest, delay or at least oppose the progression of the specific pathogenic processes underlying Parkinson's disease. The purpose of this review, based on recent biological and genetic data to be validated with appropriate animal models, was to re-examine the putative neuroprotective agents in Parkinson's disease and discuss the development of new strategies with the ultimate goal of demonstrating neurocytoprotective activity in this neurodegenerative disease. Since guidelines for research on neurocytoprotective drugs remain to be written, innovation will be the key to success of future clinical trials. It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases.
DOI: 10.1016/j.pneurobio.2007.10.003
PubMed: 18037225
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D32
Links to Exploration step
pubmed:18037225Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Disease-modifying drugs and Parkinson's disease.</title><author><name sortKey="Allain, Herve" sort="Allain, Herve" uniqKey="Allain H" first="Hervé" last="Allain">Hervé Allain</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, 2 av. du Pr Léon Bernard, F-35043 Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, 2 av. du Pr Léon Bernard, F-35043 Rennes</wicri:regionArea></affiliation></author><author><name sortKey="Bentue Ferrer, Daniele" sort="Bentue Ferrer, Daniele" uniqKey="Bentue Ferrer D" first="Danièle" last="Bentué-Ferrer">Danièle Bentué-Ferrer</name></author><author><name sortKey="Akwa, Yvette" sort="Akwa, Yvette" uniqKey="Akwa Y" first="Yvette" last="Akwa">Yvette Akwa</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18037225</idno><idno type="pmid">18037225</idno><idno type="doi">10.1016/j.pneurobio.2007.10.003</idno><idno type="wicri:Area/PubMed/Corpus">000D32</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D32</idno><idno type="wicri:Area/PubMed/Curation">000C92</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C92</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Disease-modifying drugs and Parkinson's disease.</title><author><name sortKey="Allain, Herve" sort="Allain, Herve" uniqKey="Allain H" first="Hervé" last="Allain">Hervé Allain</name><affiliation wicri:level="1"><nlm:affiliation>Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, 2 av. du Pr Léon Bernard, F-35043 Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, 2 av. du Pr Léon Bernard, F-35043 Rennes</wicri:regionArea></affiliation></author><author><name sortKey="Bentue Ferrer, Daniele" sort="Bentue Ferrer, Daniele" uniqKey="Bentue Ferrer D" first="Danièle" last="Bentué-Ferrer">Danièle Bentué-Ferrer</name></author><author><name sortKey="Akwa, Yvette" sort="Akwa, Yvette" uniqKey="Akwa Y" first="Yvette" last="Akwa">Yvette Akwa</name></author></analytic><series><title level="j">Progress in neurobiology</title><idno type="ISSN">0301-0082</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (pharmacology)</term><term>Apoptosis (drug effects)</term><term>Apoptosis (genetics)</term><term>Brain (drug effects)</term><term>Brain (metabolism)</term><term>Brain (physiopathology)</term><term>Cytoprotection (drug effects)</term><term>Cytoprotection (physiology)</term><term>Disease Models, Animal</term><term>Humans</term><term>Nerve Degeneration (drug therapy)</term><term>Nerve Degeneration (genetics)</term><term>Nerve Degeneration (physiopathology)</term><term>Neuroprotective Agents (pharmacology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term><term>Brain</term><term>Cytoprotection</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Nerve Degeneration</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Apoptosis</term><term>Nerve Degeneration</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cytoprotection</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term><term>Nerve Degeneration</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Symptomatic medications, l-Dopa and dopaminergic agents, remain the only clinically pertinent pharmacological treatment proven effective and available for the large population of patients with Parkinson's disease. The challenge for the pharmaceutical industry is to develop disease-modifying drugs which could arrest, delay or at least oppose the progression of the specific pathogenic processes underlying Parkinson's disease. The purpose of this review, based on recent biological and genetic data to be validated with appropriate animal models, was to re-examine the putative neuroprotective agents in Parkinson's disease and discuss the development of new strategies with the ultimate goal of demonstrating neurocytoprotective activity in this neurodegenerative disease. Since guidelines for research on neurocytoprotective drugs remain to be written, innovation will be the key to success of future clinical trials. It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18037225</PMID><DateCreated><Year>2007</Year><Month>12</Month><Day>21</Day></DateCreated><DateCompleted><Year>2008</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2007</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0301-0082</ISSN><JournalIssue CitedMedium="Print"><Volume>84</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Progress in neurobiology</Title><ISOAbbreviation>Prog. Neurobiol.</ISOAbbreviation></Journal><ArticleTitle>Disease-modifying drugs and Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>25-39</MedlinePgn></Pagination><Abstract><AbstractText>Symptomatic medications, l-Dopa and dopaminergic agents, remain the only clinically pertinent pharmacological treatment proven effective and available for the large population of patients with Parkinson's disease. The challenge for the pharmaceutical industry is to develop disease-modifying drugs which could arrest, delay or at least oppose the progression of the specific pathogenic processes underlying Parkinson's disease. The purpose of this review, based on recent biological and genetic data to be validated with appropriate animal models, was to re-examine the putative neuroprotective agents in Parkinson's disease and discuss the development of new strategies with the ultimate goal of demonstrating neurocytoprotective activity in this neurodegenerative disease. Since guidelines for research on neurocytoprotective drugs remain to be written, innovation will be the key to success of future clinical trials. It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allain</LastName><ForeName>Hervé</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, 2 av. du Pr Léon Bernard, F-35043 Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bentué-Ferrer</LastName><ForeName>Danièle</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Akwa</LastName><ForeName>Yvette</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neurobiol</MedlineTA><NlmUniqueID>0370121</NlmUniqueID><ISSNLinking>0301-0082</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019610" MajorTopicYN="N">Cytoprotection</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>240</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18037225</ArticleId><ArticleId IdType="pii">S0301-0082(07)00188-8</ArticleId><ArticleId IdType="doi">10.1016/j.pneurobio.2007.10.003</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C92 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000C92 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:18037225
|texte= Disease-modifying drugs and Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18037225" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |